StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

Stock analysts at StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report issued on Monday. The brokerage set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Stock Down 8.1 %

NYSE BTX opened at $0.91 on Monday. Brooklyn ImmunoTherapeutics has a 12-month low of $0.17 and a 12-month high of $10.10. The company has a market capitalization of $53.53 million, a PE ratio of -0.44 and a beta of 4.61. The firm’s 50 day moving average is $1.42 and its 200-day moving average is $1.75.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.